BioCentury | Mar 9, 2021
Politics, Policy & Law

Biopharmas ask Biden to reject compulsory licensing of COVID-19 medicines

The U.S. biopharmaceutical industry is urging the Biden administration to oppose a proposal for the World Trade Organization to issue a waiver of IP protections for COVID-19 vaccines and drugs. The industry push comes ahead...
BioCentury | Mar 8, 2021
Management Tracks

ArsenalBio bolsters team via hirings of Sirichoke, Schroer; plus Moderna, Jubilant and Synlogic

Cell therapy company Arsenal Biosciences Inc. hired Tim Sirichoke as chief technical operations officer and John Schroer as CFO. Most recently Sirichoke was VP of individualized neo-antigen specific therapies manufacturing at Genentech Inc.; he also...
BioCentury | Mar 8, 2021
Deals

March 8 Quick Takes: Roivant to acquire Immunovant; plus Lilly-Biolojic, Soleno, Gilead, Genentech and Cara-Vifor

Immunovant Inc. (NASDAQ:IMVT) rose $1.88 (14%) to $15.39 on Monday after the autoimmune company said parent Roivant Sciences Ltd. plans to propose an offer to acquire the 42.5% of outstanding shares of Immunovant that Roivant...
BioCentury | Mar 6, 2021
Management Tracks

Winter to lead BeiGene’s European commerical ops; plus Dyne, Axcella, Prometheus and more

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) hired Gerwin Winter as SVP and head of commercial for Europe. Winter was previously SVP and head of Europe at Portola Pharmaceuticals Inc. before its acquisition by Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)....
BioCentury | Mar 6, 2021
Product Development

March 5 Quick Takes: A regulatory first for Actemra; plus updates from Lilly-Incyte, Kronos, Junshi, United Therapeutics, Pfizer, Sumitomo Dainippon, Arena, Oyster Point, Azura

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said FDA approved Actemra tocilizumab to treat systemic sclerosis-associated interstitial lung disease, making it the first approved biologic for the disorder. FDA based the approval on data...
BioCentury | Mar 6, 2021
Product Development

The pace of new modality approvals is picking up

Last week’s FDA approval of Sarepta’s Amondys 45 marks the ninth new modality drug to be approved in the last year, a sign that the pace of new therapeutic formats making it to...
BioCentury | Mar 6, 2021
Emerging Company Profile

Proxygen’s knockout take on targeted protein degradation

Austrian newco Proxygen is identifying cancer therapies that act via protein degradation by screening candidates in cells that can’t send proteins to the trash. Founded last May, Proxygen GmbH has raised seed funding from the Austrian government...
BioCentury | Mar 6, 2021
Emerging Company Profile

Araris: universal linkers for antibody-drug conjugates

Araris is developing antibody-drug conjugate linker technology that could widen the therapeutic window for ADCs by improving their stability and solubility. In addition, the Swiss biotech’s peptide linkers...
BioCentury | Mar 6, 2021
Deals

How Bayer is building a cell and gene therapy business through deals

After spending the last year laying the groundwork for its entrance into cell and gene therapies through dealmaking, Bayer is expanding its external innovation search to new indications and earlier-stage...
BioCentury | Mar 6, 2021
Finance

With $106M series C, Tenaya will bring AAV manufacturing in-house

With $106 million in new series C funding, Tenaya will internalize its AAV manufacturing capabilities and continue to advance its suite of gene therapy, cellular regeneration and precision medicine platforms for heart disease.  Tenaya Therapeutics...
Items per page:
1 - 10 of 48288
BioCentury | Mar 9, 2021
Politics, Policy & Law

Biopharmas ask Biden to reject compulsory licensing of COVID-19 medicines

The U.S. biopharmaceutical industry is urging the Biden administration to oppose a proposal for the World Trade Organization to issue a waiver of IP protections for COVID-19 vaccines and drugs. The industry push comes ahead...
BioCentury | Mar 8, 2021
Management Tracks

ArsenalBio bolsters team via hirings of Sirichoke, Schroer; plus Moderna, Jubilant and Synlogic

Cell therapy company Arsenal Biosciences Inc. hired Tim Sirichoke as chief technical operations officer and John Schroer as CFO. Most recently Sirichoke was VP of individualized neo-antigen specific therapies manufacturing at Genentech Inc.; he also...
BioCentury | Mar 8, 2021
Deals

March 8 Quick Takes: Roivant to acquire Immunovant; plus Lilly-Biolojic, Soleno, Gilead, Genentech and Cara-Vifor

Immunovant Inc. (NASDAQ:IMVT) rose $1.88 (14%) to $15.39 on Monday after the autoimmune company said parent Roivant Sciences Ltd. plans to propose an offer to acquire the 42.5% of outstanding shares of Immunovant that Roivant...
BioCentury | Mar 6, 2021
Management Tracks

Winter to lead BeiGene’s European commerical ops; plus Dyne, Axcella, Prometheus and more

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) hired Gerwin Winter as SVP and head of commercial for Europe. Winter was previously SVP and head of Europe at Portola Pharmaceuticals Inc. before its acquisition by Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)....
BioCentury | Mar 6, 2021
Product Development

March 5 Quick Takes: A regulatory first for Actemra; plus updates from Lilly-Incyte, Kronos, Junshi, United Therapeutics, Pfizer, Sumitomo Dainippon, Arena, Oyster Point, Azura

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said FDA approved Actemra tocilizumab to treat systemic sclerosis-associated interstitial lung disease, making it the first approved biologic for the disorder. FDA based the approval on data...
BioCentury | Mar 6, 2021
Product Development

The pace of new modality approvals is picking up

Last week’s FDA approval of Sarepta’s Amondys 45 marks the ninth new modality drug to be approved in the last year, a sign that the pace of new therapeutic formats making it to...
BioCentury | Mar 6, 2021
Emerging Company Profile

Proxygen’s knockout take on targeted protein degradation

Austrian newco Proxygen is identifying cancer therapies that act via protein degradation by screening candidates in cells that can’t send proteins to the trash. Founded last May, Proxygen GmbH has raised seed funding from the Austrian government...
BioCentury | Mar 6, 2021
Emerging Company Profile

Araris: universal linkers for antibody-drug conjugates

Araris is developing antibody-drug conjugate linker technology that could widen the therapeutic window for ADCs by improving their stability and solubility. In addition, the Swiss biotech’s peptide linkers...
BioCentury | Mar 6, 2021
Deals

How Bayer is building a cell and gene therapy business through deals

After spending the last year laying the groundwork for its entrance into cell and gene therapies through dealmaking, Bayer is expanding its external innovation search to new indications and earlier-stage...
BioCentury | Mar 6, 2021
Finance

With $106M series C, Tenaya will bring AAV manufacturing in-house

With $106 million in new series C funding, Tenaya will internalize its AAV manufacturing capabilities and continue to advance its suite of gene therapy, cellular regeneration and precision medicine platforms for heart disease.  Tenaya Therapeutics...
Items per page:
1 - 10 of 48288